科兴制药(688136) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥322,637,429.95, representing a year-on-year increase of 19.62%[5] - The net profit attributable to shareholders was a loss of ¥8,766,132.94, reflecting a decrease of 130.11% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥12,471,455.76, down 144.79% year-on-year[5] - The net cash flow from operating activities was a negative ¥46,596,985.36, a decline of 343.13% compared to the previous year[5] - Operating profit for Q1 2023 was -¥17,131,632.71, a decline from a profit of ¥30,436,415.62 in Q1 2022[20] - The company reported a net loss of ¥17,307,133.56 for Q1 2023, compared to a net profit of ¥30,315,051.61 in Q1 2022[20] - In Q1 2023, the company reported a net loss of CNY 9,859,490.11, compared to a net profit of CNY 29,109,430.39 in Q1 2022, indicating a significant decline in profitability[21] - The company's basic and diluted earnings per share for Q1 2023 were both CNY -0.04, down from CNY 0.38 in the same period last year[21] Research and Development - Research and development expenses totaled ¥48,607,343.41, an increase of 63.45% year-on-year, accounting for 15.07% of operating revenue, up 4.04 percentage points[6] - Research and development expenses increased to ¥48,607,343.41 in Q1 2023, compared to ¥29,737,687.82 in Q1 2022, reflecting a growth of 63.4%[20] - The company plans to continue investing in R&D to enhance product offerings and market competitiveness[20] - The company is actively advancing the Phase I clinical trial of human interferon α1b inhalation solution, with the first subject enrolled in January 2023[14] - The State Drug Administration accepted the clinical trial application for "human growth hormone injection" in April 2022, indicating progress in product development[14] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,117,663,584.05, a decrease of 1.30% from the end of the previous year[6] - The total assets as of Q1 2023 amounted to ¥3,117,663,584.05, a decrease from ¥3,158,711,687.22 at the end of the previous period[17] - Total liabilities for Q1 2023 were ¥1,319,301,301.44, down from ¥1,352,870,907.21 in the previous period[17] - The company's equity attributable to shareholders was ¥1,801,984,263.00, slightly down from ¥1,808,369,403.23 in the previous period[17] Cash Flow - Cash and cash equivalents decreased to ¥126,385,765.00 from ¥162,693,510.00, indicating a reduction of 22.3%[17] - The company's cash and cash equivalents were reported at ¥483,679,482.09, down from ¥785,382,355.26, indicating a significant decrease of about 38.4%[15] - Cash and cash equivalents at the end of Q1 2023 totaled CNY 482,267,798.61, down from CNY 885,852,798.64 at the end of Q1 2022[23] - The company experienced a net decrease in cash and cash equivalents of CNY -301,702,977.66 in Q1 2023, contrasting with a net increase of CNY 11,075,926.74 in Q1 2022[23] - Operating cash inflow for Q1 2023 was CNY 322,682,139.39, a slight increase from CNY 302,960,530.43 in Q1 2022[22] - The net cash flow from operating activities was CNY -46,596,985.36, worsening from CNY -10,515,309.38 in Q1 2022[22] - Investment activities resulted in a net cash outflow of CNY -296,153,447.14, compared to CNY -127,319,389.61 in the previous year[23] - The company received CNY 360,000,000.00 from investment recoveries in Q1 2023, significantly higher than CNY 160,000,000.00 in Q1 2022[23] - Total cash inflow from financing activities was CNY 158,810,321.95, compared to CNY 198,816,633.02 in Q1 2022[23] - The company reported a cash outflow of CNY 101,989,908.60 for debt repayment in Q1 2023, up from CNY 39,500,000.00 in the same period last year[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,868[10] - The top shareholder, Qingdao Hengyi Enterprise Management Partnership, holds 2,440,999 shares, representing a significant portion of the company's equity[13] - The total number of shares held by the top ten shareholders includes significant stakes from natural persons such as Nie Rulong and Zhu Nengshun, with holdings of 1,888,888 and 1,740,217 shares respectively[13]